|
|
Lupus nephritis-novel diagnostic and therapeutic approaches
Pešičková, Satu ; Tesař, Vladimír (advisor) ; Teplan, Vladimír (referee) ; Krejčí, Karel (referee)
Key words: anti-mCRP antibodies, cyclophosphamide, cyclosporine A, lupus nephritis, systemic lupus erythematosus Systemic lupus erythematosus (SLE) is a systemic autoimmune disease. Circulating autoantibodies against the body's own nuclear and cytoplasmic structures and creation of immune complexes play a key role in the pathogenesis of SLE. Antibodies against monomeric C-reactive protein (anti-mCRP) might play role in pathogenesis of lupus nephritis (LN). The aim of this study was to find relation between anti-mCRP and activity of LN and response to therapy. Methods: The study was performed on 57 patients (M/F 0.21, median age 32 years) with LN. In a subanalysis, we focused on 29 patients with newly diagnosed active LN and we followed them up for a median of 5.9 years. Levels of anti-CRP were measured by in house ELISA. Disease activity was measured by SLEDAI. Results: Levels of anti-mCRP were significantly higher in patients with active lupus nephritis (26.78 versus 7.5 AU, p=0.009) and levels of anti-mCRP positively correlated with the activity of SLE as assessed by the SLEDAI score (Spearman's r=0.406, p= 0.002). We found negative prediction of anti-mCRP for worse outcome after two years of standard therapy, OR (95% CI)=13.7 (1.22-770.87); p=0.014. Conclusion: Serum levels of anti-mCRP seem to...
|
|
|
Lupus nephritis-novel diagnostic and therapeutic approaches
Pešičková, Satu ; Tesař, Vladimír (advisor) ; Teplan, Vladimír (referee) ; Krejčí, Karel (referee)
Key words: anti-mCRP antibodies, cyclophosphamide, cyclosporine A, lupus nephritis, systemic lupus erythematosus Systemic lupus erythematosus (SLE) is a systemic autoimmune disease. Circulating autoantibodies against the body's own nuclear and cytoplasmic structures and creation of immune complexes play a key role in the pathogenesis of SLE. Antibodies against monomeric C-reactive protein (anti-mCRP) might play role in pathogenesis of lupus nephritis (LN). The aim of this study was to find relation between anti-mCRP and activity of LN and response to therapy. Methods: The study was performed on 57 patients (M/F 0.21, median age 32 years) with LN. In a subanalysis, we focused on 29 patients with newly diagnosed active LN and we followed them up for a median of 5.9 years. Levels of anti-CRP were measured by in house ELISA. Disease activity was measured by SLEDAI. Results: Levels of anti-mCRP were significantly higher in patients with active lupus nephritis (26.78 versus 7.5 AU, p=0.009) and levels of anti-mCRP positively correlated with the activity of SLE as assessed by the SLEDAI score (Spearman's r=0.406, p= 0.002). We found negative prediction of anti-mCRP for worse outcome after two years of standard therapy, OR (95% CI)=13.7 (1.22-770.87); p=0.014. Conclusion: Serum levels of anti-mCRP seem to...
|
guest ::
